Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

Caroline Klint Johannesen, a, b Omid Rezahosseini, b, c Mikkel Gybel-Brask, c Jonas Henrik Kristensen, d,e Rasmus Bo Hasselbalch, d,e,f Mia Marie Pries-Heje, g Pernille Brok Nielsen, a,b,c,d,e Andreas Dehlbæk Knudsen, h,i Kamille Fogh, d,e Jakob Boesgaard Norsk, d,e Ove Andersen, f,i Claus Antonio Juul Jensen, i Christian Torp-Pedersen, k,l,m Jørgen Rungbjy, n,o Sisse Bolm Ditlev, n,o Ida Hageman, n Rasmus Mogelvang, n Ram B. Dessau, n Erik Sørensen, c, d,e Lene Holm Harritshøj, f Fredrik Folke, o Curt Sten, n Maria Elizabeth Engel Møller, f Frederik Neess Engsig, g Henrik Ullum, m Charlotte Sværke Jørgensen, m Sisse R. Ostrowski, c,f Henning Bundgaard, f,g Kasper Karmark Iversen, k,o,f Thea Kølsen Fischer, a,b,x Susanne Dam Nielsen, b,f

aDepartment of Clinical Research, Nordsjællands Hospital, Hillerød, Denmark
bViro-immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
cDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark
dDepartment of Cardiology, Herlev og Gentofte Hospital, University of Copenhagen, Herlev, Denmark
eDepartment of Emergency Medicine, Herlev og Gentofte Hospital, University of Copenhagen, Herlev, Denmark
fDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
gDepartment of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
hDepartment of Emergency, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
iDepartment of Clinical Research, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
jDepartment of Clinical Biochemistry, Copenhagen University Hospital – Nordsjællands Hospital, Hillerød, Denmark
kDepartment of Cardiology and Clinical Research, Nordsjællands Hospital, Hillerød, Denmark
lDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark
mDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark
nDepartment of Endocrinology, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Bispebjerg, Copenhagen, Denmark
oDepartment of Pulmonary Medicine, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Bispebjerg, Copenhagen, Denmark
pMental Health Services-The Capital Region of Denmark, Copenhagen, Denmark
qDepartment of Clinical Microbiology, Zealand University Hospital–Slagelse, Slagelse, Denmark
rDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark
sCopenhagen University Hospital–Copenhagen Emergency Medical Services, Copenhagen, Denmark
tDiagnostik Enhed, Copenhagen University Hospital, Bornholm, Denmark
uDepartment of Infectious Disease, Copenhagen University Hospital–Amager and Hvidovre, Hvidovre, Denmark
vStatens Serum Institut, Copenhagen, Denmark
wDepartment of Public Health, Global Health Section, University of Copenhagen, Copenhagen, Denmark

Caroline Klint Johannesen and Omid Rezahosseini contributed equally, and Thea Kølsen Fischer and Susanne Dam Nielsen contributed equally to this article. The order of names was determined according to the criteria for authorship of the International Committee of Medical Journal Editors (ICMJE).

ABSTRACT Most individuals seroconvert after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but being seronegative is observed in 1 to 9%. We aimed to investigate the risk factors associated with being seronegative following PCR-confirmed SARS-CoV-2 infection. In a prospective cohort study, we screened health care workers (HCW) in the Capital Region of Denmark for SARS-CoV-2 antibodies. We performed three rounds of screening from April to October 2020 using an enzyme-linked immunosorbent assay (ELISA) method targeting SARS-CoV-2 total antibodies. Data on all participants’ PCR for SARS-CoV-2 RNA were captured from national registries. The Kaplan-Meier method and Cox proportional hazards models were applied to investigate the probability of being seronegative and the related risk factors, respectively. Of 36,583 HCW, 866 (2.4%)
had a positive PCR before or during the study period. The median (interquartile range [IQR]) age of 866 HCW was 42 (31 to 53) years, and 666 (77%) were female. After a median of 132 (range, 35 to 180) days, 21 (2.4%) of 866 were seronegative. In a multivariable model, independent risk factors for being seronegative were self-reported asymptomatic or mild infection hazard ratio (HR) of 6.6 (95% confidence interval [CI], 2.6 to 17; \( P < 0.001 \)) and body mass index (BMI) of \( \geq 30 \), HR 3.1 (95% CI, 1.1 to 8.8; \( P = 0.039 \)). Only a few (2.4%) HCW were not seropositive. Asymptomatic or mild infection as well as a BMI above 30 were associated with being seronegative. Since the presence of antibodies against SARS-CoV-2 reduces the risk of reinfection, efforts to protect HCW with risk factors for being seronegative may be needed in future COVID-19 surges.

**IMPORTANCE** Most individuals seroconvert after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but negative serology is observed in 1 to 9%. We found that asymptomatic or mild infection as well as a BMI above 30 were associated with being seronegative. Since the presence of antibodies against SARS-CoV-2 reduces the risk of reinfection, efforts to protect HCW with risk factors for being seronegative may be needed in future COVID-19 surges.

**KEYWORDS** asymptomatic infections, body mass index, health care workers, risk factor, SARS-CoV-2, seroconversion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has as of June 2021 affected more than 176 million individuals and caused more than 3.8 million deaths worldwide (1). Both the humoral and the cellular immune systems react to SARS-CoV-2 infection, and the vast majority of individuals infected by SARS-CoV-2 have detectable antibodies 3 weeks after infection (2, 3), but 1 to 9% are seronegative (3, 4). It has been shown that the presence of anti-spike or anti-nucleocapsid IgG antibodies reduces the risk of SARS-CoV-2 reinfection (5, 6). As such, it is important to determine the risk factors for being seronegative. We aimed to investigate the risk factors for being seronegative following PCR-confirmed SARS-CoV-2 infection in a large prospective cohort of health care workers (HCW) in Denmark (7).

**RESULTS**

Of 36,583 HCW who participated in any of the three rounds of screening, 866 (2.4%) had a positive PCR test and were included in this study. Participants contributed with 94,377 person-days of follow up with a median (interquartile range [IQR]) of 132 (35 to 180) days of follow-up per HCW. The median (IQR) age was 42 (31 to 53) years, and 666 (77%) were female (Table 1).

The median (IQR) time between a positive PCR and an enzyme-linked immunosorbent assay (ELISA) antibody test was 18 (14 to 30), 55 (42 to 64), and 172 (153 to 187) days for screening rounds 1, 2, and 3, respectively. A total of 483 (56%) out of 866 HCW participated in more than one screening round, and 116 (13%) participated in all three rounds. Of the 866 HCW, 21 (2.4%) had no detectable antibodies at last follow-up.

Among participants who all had a positive PCR, 540/866 (62%) reported having had symptomatic SARS-CoV-2 infection, and 253/866 (29%) reported no or mild symptoms.

One participant was seronegative at the first test after a positive PCR (66 days after PCR) but seropositive at the second test (182 days after PCR). We only included the first test after PCR if it was more than 9 days after the positive PCR test. Three participants did not meet the time-between-test cutoff but were seronegative shortly after their PCR-test and seropositive in the following serum samples tested.

**Risk factors for being seronegative.** In a univariable Cox proportional hazards model, participants who had self-reported mild or no symptoms had a significantly increased risk of being seronegative with a hazard ratio (HR) of 7.0 (95% confidence interval [CI], 2.7 to 18; \( P < 0.001 \)) compared to participants who were clinically...
Participants with a body mass index (BMI) above 30 kg/m² versus participants with a BMI lower than 25 kg/m² had an HR of 3.0 (95% CI, 1.0 to 8.6; \( P = 0.043 \)) for being seronegative. In a multivariate Cox proportional hazards model, including both BMI and severity of disease, we found almost the same results (Table 2).

Figure 1 presents the probability of being seronegative over time since positive PCR test, stratified by self-reported level of symptoms in two categories, no clinical symptom or mild clinical symptoms and clinically symptomatic and bedridden at home or at hospital. The risk of being seronegative is higher among participants with no symptoms or mild symptoms, and the difference in risk increases over time. After 200 days of follow-up, the risk is estimated to be 13% (95% CI, 5.7 to 20) in participants with no or mild symptoms and 1.9% (95% CI, 0.7 to 3.5) in participants bedridden at home or at hospital.

### TABLE 1 Characteristics of the participants in total and divided by serostatus

| Characteristic                        | n (%) (N = 866) | ELISA seropositive n (%) (N = 845) | ELISA seronegative n (%) (N = 21) |
|---------------------------------------|-----------------|-----------------------------------|----------------------------------|
| Age                                   |                 |                                   |                                  |
| <40                                   | 380 (44)        | 369 (44)                          | 11 (52)                          |
| 40–60                                 | 385 (44)        | 376 (45)                          | 9 (43)                           |
| >60                                   | 101 (12)        | 100 (12)                          | 1 (4.8)                          |
| Sex                                    |                 |                                   |                                  |
| Female                                | 666 (77)        | 647 (77)                          | 19 (90.5)                        |
| Male                                  | 200 (23)        | 198 (23)                          | 2 (9.5)                          |
| BMI                                    |                 |                                   |                                  |
| <25                                   | 423 (49)        | 415 (49)                          | 8 (38)                           |
| 25–30                                 | 241 (28)        | 234 (28)                          | 7 (33)                           |
| 30                                    | 109 (13)        | 103 (12)                          | 6 (29)                           |
| No information                        | 93 (11)         | 93 (11)                           | 0 (0)                            |
| Smoking                               |                 |                                   |                                  |
| Yes                                   | 96 (11)         | 95 (11)                           | 1 (4.8)                          |
| No                                    | 754 (87)        | 734 (87)                          | 20 (95.2)                        |
| No information                        | 16 (1.9)        | 16 (1.9)                          | 0 (0)                            |
| Reported having contact with patients |                 |                                   |                                  |
| Yes                                   | 810 (93.5)      | 790 (93.5)                        | 20 (95.2)                        |
| No                                    | 55 (6.4)        | 54 (6.4)                          | 1 (4.8)                          |
| No information                        | 1 (0.1)         | 1 (0.1)                           | 0 (0)                            |
| Severity of the disease               |                 |                                   |                                  |
| No clinical symptom or clinically     | 253 (29)        | 238 (28)                          | 15 (71)                          |
| symptomatic but quite well at home    |                 |                                   |                                  |
| Clinically symptomatic and bedridden  | 540 (62)        | 534 (63)                          | 6 (29)                           |
| at home or at hospital                |                 |                                   |                                  |
| No information                        | 73 (8.4)        | 73 (8.6)                          | 0 (0)                            |
| Median time since PCR (days)          | 131             | 136                               | 80                               |

symptomatic. Participants with a body mass index (BMI) above 30 kg/m² versus participants with a BMI lower than 25 kg/m² had an HR of 3.0 (95% CI, 1.0 to 8.6; \( P = 0.043 \)) for being seronegative. In a multivariate Cox proportional hazards model, including both BMI and severity of disease, we found almost the same results (Table 2).

Figure 1 presents the probability of being seronegative over time since positive PCR test, stratified by self-reported level of symptoms in two categories, no clinical symptom or mild clinical symptoms and clinically symptomatic and bedridden at home or at hospital. The risk of being seronegative is higher among participants with no symptoms or mild symptoms, and the difference in risk increases over time. After 200 days of follow-up, the risk is estimated to be 13% (95% CI, 5.7 to 20) in participants with no or mild symptoms and 1.9% (95% CI, 0.7 to 3.5) in participants bedridden at home or at hospital.

### TABLE 2 Risk factors for negative anti-SARS-CoV-2 antibody in adjusted and unadjusted Cox regression models⁴

| Characteristic                        | Unadjusted HR (95% CI) | \( P \) value | Adjusted HR (95% CI) | \( P \) value |
|---------------------------------------|------------------------|---------------|----------------------|---------------|
| BMI                                    |                        |               |                      |               |
| <25                                   | 1.0 (reference)        |               |                      |               |
| 25–30                                 | 1.4 (0.50 to 3.8)      | 0.618         | 1.4 (0.52–4.0)⁴     | 0.484         |
| >30                                   | 3.0 (1.0–8.6)          | 0.043         | 3.1 (1.1–8.8)⁴      | 0.039         |
| Severity of disease                   |                        |               |                      |               |
| Clinically symptomatic and bedridden  | 1.0 (reference)        | <0.001        | 6.6 (2.6–17)⁴       | <0.001        |
| at home or at hospital                |                        |               |                      |               |
| No clinical symptom or clinically     | 7.0 (2.7–18)           | <0.001        |                      |               |
| symptomatic but quite well at home    |                        |               |                      |               |

⁴BMI, body mass index; CI, confidence interval; HR, hazard ratio.
⁵Adjusted for severity of disease and age.
⁶Adjusted for BMI category and age.
DISCUSSION

In this large cohort of HCW with PCR-confirmed SARS-CoV-2 infection, we found that only 2.4% were seronegative. Asymptomatic or mildly symptomatic SARS-CoV-2 infection and obesity were associated with being seronegative.

Compared to symptomatic HCW, those who were asymptomatic or had mild symptoms were at almost seven times higher risk of being seronegative, corroborating previous reports (8–11). It has been reported that severity of COVID-19 affects the initial magnitude but not persistence of antibodies (3). Although a recent study demonstrated that antibodies decline over time and their half-life is positively associated with the intensity of the initial response (12). We do not present data implying a correlation between initial antibody response and antibody persistence, as we did not measure antibody titers initially or at the following time points. These controversies could be partly due to different ELISAs that were applied. Unlike traditional indirect ELISAs (antigen-antibody-antibody), antigen sandwich assay (antigen-antibody-antigen) uses a labeled virus antigen instead of labeled secondary anti-human antibody for detection, so that each anti-SARS-CoV-2 antibody bridges two recombinant antigens of the virus that affect the sensitivity of the test (13).

It has been shown that the presence of antibodies against other seasonal human coronaviruses (other than SARS-CoV-2) can protect against a severe course of COVID-19 (14). We did not have information about prior infection with other human coronaviruses, but because the severity of COVID-19 is associated with risk of being seronegative, it seems relevant to adjust results in future studies. In addition, smoking is associated with COVID-19 severity and progression (15), although we could not find a significant association between smoking status and being seronegative.

In comparison with a BMI of <25 kg/m², participants with a BMI of >30 had a three times higher risk of being seronegative even after adjustment for severity of the disease. Obesity causes leptin and insulin resistance and is accompanied by systemic low-grade inflammation, causing high levels of proinflammatory cytokines and a hampered cellular response to viral infections (16). A diminished response can thus also be the case with patients with obesity and SARS-CoV-2-infection, thus leading to increased awareness of the risk of reinfection. Policy makers could consider this for vaccination.
or revaccination of HCWs. Furthermore, it is worth mentioning that there could be residual confounding factors that we did not adjust for.

The large sample size, extensive follow-up, and prospective gathering of data were strengths of our study. Furthermore, we had access to complete data on SARS-CoV-2 PCR from the Danish Microbiology Database (MiBa), which contains all data on microbiological samples in Denmark. Finally, we used the Wantai ELISA, which is one of the most sensitive assays available (17). However, Wantai ELISA is an antigen sandwich assay, and the results may only be applicable to antigen bridging assays and only for a limited time interval. Other assays could produce different results. In addition, the study was limited to HCW, and therefore, we did not have any elderly in the population or participants who were chronically too ill to work. This meant that there were almost no cases of SARS-CoV-2 hospitalizations in the data set and no cases of either admission to intensive care units or death in our study population. Furthermore, the information on participants was collected at the time of inclusion in the study population. The survey did not include questions about immunodeficiency conditions or any metabolic or systemic disturbance factors.

In conclusion, 2.4% of HCW were seronegative after PCR confirmed COVID-19 infection. Asymptomatic or mild infection and a BMI higher than 30 were associated with being seronegative. It has been shown that presence of antibodies considerably reduces the risk of SARS-CoV-2 reinfection, and efforts to protect HCW with these risk factors in subsequent COVID-19 surges may be needed.

MATERIALS AND METHODS

Study design and participants. We used data from a prospective cohort study, where all HCW and other staff employed at hospitals and primary care facilities in the Capital Region of Denmark were invited to participate in a screening program for SARS-CoV-2 antibodies. As previously described (7), screening was offered in three rounds (from early April to early October 2020). All participants provided blood samples for SARS-CoV-2 serology and were asked to fill in a questionnaire on exposures, risk factors, and symptoms of COVID-19. Participants who provided blood at least once after a positive PCR were included into the analyses. The study was registered with the Danish Data Protection Authorities (P-2020-361) and presented to the regional scientific ethics committee of the Capital Region (Jnr-H-20026288), which concluded that the study did not require a scientific ethical approval. The study was registered at ClinicalTrials.gov under registration no. NCT04346186.

SARS-CoV-2 antibody measurement using ELISA. SARS-CoV-2 total antibodies were measured qualitatively by a double-antigen bridging enzyme-linked-immunosorbent assay (ELISA) targeting the SARS-CoV-2 receptor-binding domain (S-RBD) (Wantai BioPharm, Beijing, China) according to the manufacturer’s instructions. A signal/cutoff ratio of ≥1/1 was interpreted as positive. This ELISA was previously validated yielding a sensitivity of 96.7% and a specificity of 99.5% (17).

SARS-CoV-2 PCR-testing. During the study period, HCW were advised to test at regular intervals with or without symptoms. Results from the general Danish PCR-testing program were captured from the Danish Health Data Agency and linked to participants through the Civil Registration System, using the unique personal identification number as described elsewhere (18). Real-time PCR (RT-PCR) analyses for SARS-CoV-2 RNA were performed at Statens Serum Institute (SSI) and TestCenter Denmark using primers targeting the E gene. A test was defined as positive if the cycle threshold value was ≤38. The results from these tests were made available to researchers in a categorical format (positive, negative, never tested).

Definitions. To ensure sufficient time from infection to seroconversion, we included ELISA results only if blood sampling was done more than 9 days after a positive PCR test (2).

Disease severity was self-reported as no or mild symptoms (no clinical symptom or clinically symptomatic but quite well) and symptomatic (clinically symptomatic and bedridden at home or hospitalized).

Statistical analyses. Proportions are presented as percentages, and continuous data as medians with interquartile ranges (IQR). Participants were followed from a positive PCR test to the last ELISA. Survival analysis was applied to handle the differences in time from PCR-testing to the last result of ELISA antibody-detection. Time since PCR was defined in days. Where multiple serum samples were conducted, the time until the last serum sample was used. An event was defined as a serum sample with no detection of SARS-CoV-2 antibodies. Where the last serum samples were positive for SARS-CoV-2 antibodies, the participant was censored afterwards. Survival times and event probability plots were used to investigate the probability of not having detectable antibodies over time, thus the risk of being seronegative a defined time after a positive PCR test. Risk factors (age, sex, body mass index [BMI], disease severity, smoking, having contact with patients) for not having detectable antibodies after a positive PCR were investigated in uni- and multivariable Cox proportional hazards models yielding hazard ratio (HR) and 95% confidence intervals (CI). The proportional hazard assumptions were tested by plotting Schoenfeld residuals against time. All analyses were conducted in the statistical software R version 3.6.1.
REFERENCES

1. European Centre for Disease Prevention and Control. 2021. COVID-19 situation update worldwide, as of week 23, 2021. https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed 21 June 2021.

2. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, Soni D, Das S, Hasan M, Patel M, Senan AM, Goruntia S, McMillan J, Edagwa B, Eisenberg R, Gurumurthy CB, Reid SPM, Punyadeera C, Chang L, Gendelman HE. 2021. Diagnostics for SARS-CoV-2 infections. Nat Mater 20:593–605. https://doi.org/10.1038/s41563-020-00906-z.

3. L’Huillier AG, Meyer B, Andrey DO, Arm-Venize I, Baggio S, Didierlaurent A, Eberhardt CS, Eckele I, Grassett-Salomon C, Hutten A, Posfay-Barbe KM, Royo S, Pralong JA, Vuilleumier N, Yerly S, Siegenthaler C-A, Kaiser L. 2021. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clin Microbiol Infect 27:784.e1. https://doi.org/10.1016/j.cmi.2021.01.005.

4. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsdottir S, Thorsteinsdottir B, Kristjansdottir S, Birgisdottir K, Kristinsdottir AM, Sigurdsdottir MI, Arnadottir GA, Arbo K, Gudmundsdottir S, Gudmundsson KR, Gunnarsdottir OS, Gyfaslon A, Helgason A, Jonsdottir BO, Jonasson A, Jonesson H, Kristjansson T, Kristinsson KG, Magnusdottir DN, Magnusson OT, Olafsdottir LB, Rognvaldsson S, Le Roux L, Sigmundsdottir G, Sigurdsdottir A, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thordarson B, Thordardottir M, Saemundsdottir J, et al. 2020. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 383:1724–1734. https://doi.org/10.1056/NEJMoa2026116.

5. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Peck LJ, Ritter TG, de Toledo Z, Cornall RJ, Jones EY, Stuart DI, Scroen G, Ebernd H, Hoosdally S, Crook DW, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Walker TM, Jeffery K, Eyre DW, Oxford University Hospitals Staff Testing Group. 2021. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis https://doi.org/10.1093/cid/ciaa004.

6. van den Dool S, Mellema K, Veldman AM, Mijksenaar R, Eerkens MW, van den Born M, ter Schure H, Roukema H. 2021. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: a report for up to 10 months after infection. Microorganisms 9:1786. https://doi.org/10.3390/microorganisms9030356.

7. Muecksch F, Wise H, Batchelor A, Squires M, Semple E, Richardson C, McGuire J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JC, Hatzioannou T, Jenks S, Bieniasz PD. 2021. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis 223:389–398. https://doi.org/10.1093/infdis/jiaa659.

8. Papatheodorou A, Delivanis T, Zafiropoulos A, Karatzas M, Karatzas M, Zara S, Konstantinou M, Tassios P, Constanti M. 2021. Kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers. Eur J Intern Med 89:97–103. https://doi.org/10.1016/j.ejim.2021.05.028.
13. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, Stone M, Hazegh K, Grebe E, Zhang S, Ma P, Orzechowski M, Gomez JE, Livny J, Hung DT, Vassallo R, Busch MP, Dumont LJ. 2021. SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: dependency on assay format and applicability to serosurveillance. Transfusion 61:2677–2687. n/a. https://doi.org/10.1111/trf.16555.

14. Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer AE, Hanses F, Vollenberg R, Lorentzen E, Tiwari-Heckler S, Duchemin J, Elouze S, Vetter M, Fürst J, Schuster P, Brix T, Denkinger CM, Müller-Tidow C, Schmidt H, Tepasse P-R, Kühn J. 2021. Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. J Clin Virol 139:104847. https://doi.org/10.1016/j.jcv.2021.104847.

15. Patanavanich R, Glantz SA. 2021. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health 21:1554. https://doi.org/10.1186/s12889-021-11579-x.

16. Drucker DJ. 2021. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab 33:479–498. https://doi.org/10.1016/j.cmet.2021.01.016.

17. Harritshøj LH, Gybel-Brask M, Afzal S, Kamstrup PR, Jørgensen CS, Thomsen MK, Hilsted L, Friis-Hansen L, Szecsi PB, Pedersen L, Nielsen L, Hansen CB, Garred P, Korsholm T-L, Mikkelsen S, Nielsen KO, Møller BK, Hansen AT, Iversen KK, Nielsen PB, Hasselbalch RB, Fogh K, Norsk JB, Kristensen JH, Schanning K, Kirky NS, Nielsen ACY, Landsy LH, Loftager M, Holm DK, Nilsson AC, Saakmose SG, Grum-Schwensen B, Aagaard B, Jensen TG, Nielsen DM, Ullum H, Dessau RB. 2021. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol 59:e02596-20. https://doi.org/10.1128/JCM.02596-20.

18. Todsen T, Tolsgaard M, Folke F, Jakobsen KK, Ersbøll AK, Benfield T, von Buchwald C, Kirky N. 2021. SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens. Dan Med J 68:A01210087.